Disseminated Intravascular Coagulation (DIC) Market Report 2026

Disseminated Intravascular Coagulation (DIC) Market Overview

• Disseminated Intravascular Coagulation (DIC) market size has reached to $0.49 billion in 2025 • Expected to grow to $0.61 billion in 2030 at a compound annual growth rate (CAGR) of 4.8% • Growth Driver: Impact Of Rising Cancer Incidence On Coagulation Disorders • Market Trend: Next-Generation Automated Coagulation Analyzers Improve Diagnostics And Patient Management • North America was the largest region in 2025.

What Is Covered Under Disseminated Intravascular Coagulation (DIC) Market?

Disseminated intravascular coagulation (DIC) is a complex, life-threatening condition characterized by excessive blood clotting followed by severe bleeding due to the depletion of clotting factors and platelets. It is triggered by underlying conditions such as sepsis, trauma, malignancies, and obstetric complications. The main treatments of disseminated intravascular coagulation (DIC) are medicines, transfusions, surgery, and other treatment. Medicines used involve anticoagulants, blood products, and supportive drugs to regulate clotting and bleeding complications associated with DIC. Diagnostic methods encompass complete blood count with blood smear exam, partial thromboplastin time (PTT), fibrinogen blood test, d-dimer, and additional diagnostic tests. These tests are administered through various routes, including oral, parenteral, and alternative methods, and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies. Treatments are utilized across hospitals, specialty clinics, homecare settings, and other end users.

What Is The Disseminated Intravascular Coagulation (DIC) Market Growth Forecast?

The disseminated intravascular coagulation (dic) market size is expected to see steady growth in the next few years. It will grow to $0.61 billion in 2030 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to advanced coagulation diagnostics, improved critical care infrastructure, early intervention protocols, clinical research advancements, awareness programs. Major trends in the forecast period include increased focus on early diagnosis of coagulation disorders, growing use of blood component therapies, expansion of hospital-based critical care treatment, rising awareness of dic in high-risk conditions, adoption of advanced diagnostic monitoring tools.

Global Disseminated Intravascular Coagulation (DIC) Market Segmentation

1) By Treatment: Medicines, Transfusions, Surgery, Other Treatments 2) By Diagnosis: Complete Blood Count With Blood Smear Exam, Partial Thromboplastin Time (PTT), Fibrinogen Blood Test, D-dimer, Other Diagnosis 3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Medicines: Anticoagulants, Antiplatelet Drugs, Fibrinolytics, Procoagulants, Antithrombin Therapy 2) By Transfusions: Platelet Transfusion, Fresh Frozen Plasma (FFP), Cryoprecipitate Transfusion, Red Blood Cell Transfusion 3) By Surgery: Surgical Removal Of Thrombus, Organ Surgery 4) By Other Treatments: Plasma Exchange, Supportive Care, Steroid Therapy

What Is The Driver Of The Disseminated Intravascular Coagulation (DIC) Market?

The increasing prevalence of cancer is expected to drive the growth of the disseminated intravascular coagulation (DIC) market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade and destroy normal tissues. Cancer cases are rising due to factors such as the aging population, lifestyle changes, environmental exposure, infections, and genetic predisposition. Cancer can cause disseminated intravascular coagulation (DIC) by triggering excessive activation of the coagulation cascade through tumor-produced procoagulant substances, leading to widespread clotting and bleeding. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, in 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide. Projections suggest these numbers could increase to 29.9 million new cases and 15.3 million deaths annually by 2040. Therefore, the increasing prevalence of cancer is driving the growth of disseminated intravascular coagulation (DIC) industry.

Key Players In The Global Disseminated Intravascular Coagulation (DIC) Market

Major companies operating in the disseminated intravascular coagulation (dic) market are Nihon Kohden Corporation, Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Abbott Laboratories, Thermo Fisher Scientific Inc., Fresenius Kabi AG, Danaher Corporation, Siemens Healthineers, Grifols S.A., Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc

Global Disseminated Intravascular Coagulation (DIC) Market Trends and Insights

Major companies operating in the disseminated intravascular coagulation (DIC) market are focusing on leveraging advanced solutions, such as real-time hemostasis monitoring, to enhance diagnostic speed, accuracy, and intervention in critically ill patients. Real-time hemostasis monitoring refers to the continuous assessment of clot formation and coagulation parameters during testing, providing clinicians with timely insights for better management of coagulopathy. For instance, in February 2024, Roche Diagnostics, a Switzerland-based in vitro diagnostics company, launched three new coagulation assays for Factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban) on its cobas t line of automated analyzers. These assays use Roche’s cassette-based reagent system, which standardizes reagent preparation, minimizes manual handling, and delivers fast, reliable anti-Xa activity measurement, critical for managing DIC patients receiving anticoagulants.

What Are Latest Mergers And Acquisitions In The Disseminated Intravascular Coagulation (DIC) Market?

In March 2024, MediLink Therapeutics (Suzhou) Co. Ltd., a China-based biotech company, collaborated with Amgen Inc. to evaluate YL201 for treating thrombotic disorders, including disseminated intravascular coagulation (DIC). This collaboration aims to advance blood clotting therapies, enhancing treatment effectiveness and patient outcomes. Amgen Inc. is a US-based biopharmaceutical company focused on the discovery, development, and manufacturing of innovative therapeutics.

Regional Outlook

North America was the largest region in the disseminated intravascular coagulation (DIC) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Disseminated Intravascular Coagulation (DIC) Market?

The disseminated intravascular coagulation (DIC) market consists of revenues earned by entities by providing services such as pharmaceutical treatments, anticoagulant therapies, diagnostic services, and critical care interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The disseminated intravascular coagulation (DIC) market also includes sales of diagnostic tools, anticoagulant medications, and blood products such as platelets, fresh frozen plasma, or cryoprecipitate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Disseminated Intravascular Coagulation (DIC) Market Report 2026?

The disseminated intravascular coagulation (dic) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the disseminated intravascular coagulation (dic) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.